Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma

Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma

Abstract Background: Serum B‐cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value. Methods: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys‐based sBCMA assay. R...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis‐Papaiakovou, Foteini Theodorakakou, Maria Roussou, Maria Gavriatopoulou, Meletios A Dimopoulos, Efstathios Kastritis
Format: Article
Language:English
Published: Wiley 2025-02-01
Series:eJHaem
Subjects:
B‐cell maturation antigen
BCMA
multiple myeloma
overall survival
prognosis
progression‐free survival
Online Access:https://doi.org/10.1002/jha2.889

Internet

https://doi.org/10.1002/jha2.889

Similar Items